Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia


Por: Bioque, M, Mezquida, G, Amoretti, S, Garcia-Rizo, C, Lopez-Ilundain, JM, Diaz-Caneja, CM, Zorrilla, I, Mane, A, Rodriguez-Jimenez, R, Corripio, I, Pomarol-Clotet, E, Ibanez, A, Usall, J, Contreras, F, Mas, S, Vazquez-Bourgon, J, Cuesta, MJ, Parellada, M, Gonzalez-Pinto, A, Hidalgo-Figueroa, M, Bernardo, M

Publicada: 1 may 2022 Ahead of Print: 1 feb 2022
Resumen:
Relapses are frequent in the first years following a first episode of schizophrenia (FES), being associated with a higher risk of developing a chronic psychotic disorder, and poor clinical and functional outcomes. The identification and intervention over factors associated with relapses in these early phases are timely and relevant.In this study, 119 patients in remission after a FES were closely followed over three years. Participants came from the 2EPS Project, a coordinated, naturalistic, longitudinal study of 15 tertiary centers in Spain. Sociodemographic, clinical, treatment and substance abuse data were analyzed.49.6% of the participants relapsed during the 3-years follow-up. None of the baseline demographic and clinical characteristics analyzed showed a statistically significant association with relapses. 22% of patients that finished the follow-up without relapsing were not taking any antipsychotic. The group that relapsed presented higher mean antipsychotics doses (381.93 vs. 242.29 mg of chlorpromazine equivalent/day, p = 0.028) and higher rates of antipsychotic polytherapy (28.6% vs. 13%, p < 0.001), benzodiazepines use (30.8% vs. 8.5%, p < 0.001), side effects reports (39.2% vs. 25%, p = 0.022), psychological treatment (51.8% vs. 33.9%, p = 0.03), and cannabis consumption (93.2% vs. 56.7%, p < 0.001). Clozapine use was notably higher in the group that reminded in remission (21.7% vs. 8.2%, p < 0.019). These findings may guide clinicians to detect subgroups of patients with higher risk to present a second episode of psychosis, focusing on measures to ensure an adequate treatment or facilitating cannabis use cessation. This study supports future research to identify relapse prevention strategies for patients in early phases of schizophrenia.

Filiaciones:
Bioque, M:
 Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain

Mezquida, G:
 Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit, Barcelona, Spain

 Univ Barcelona, Dept Basic Clin Practice, Pharmacol Unit, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

Amoretti, S:
 Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit, Barcelona, Spain

 Hosp Univ Vall dHebron, Dept Psychiat, Madrid, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain

 Univ Barcelona, Dept Med, Barcelona, Spain

 Vall dHebron Res Inst VHIR, Psychiat Genet Unit, Grp Psychiat Mental Hlth & Addict, Barcelona, Spain

Garcia-Rizo, C:
 Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain

Lopez-Ilundain, JM:
 Complejo Hosp Navarra, Dept Psychiat, Navarra, Spain

 Biomed Network Res Ctr Mental Hlth CIBERSAM, Barcelona, Spain

Diaz-Caneja, CM:
 Univ Complutense, Hosp Gen Univ Gregorio Maranon, Inst Psychiat & Mental Hlth,Inst Invest Sanitaria, Dept Child & Adolescent Psychiat,Sch Med,CIBERSAM, Madrid, Spain

Zorrilla, I:
 Univ Basque Country, Hosp Univ Araba, Serv Psiquiatria, Madrid, Spain

 Navarra Hlth Res Inst IdiSNA, Navarra, Spain

Mane, A:
 Hosp del Mar Med Res Inst IMIM, Madrid, Spain

 Ctr Invest Biomed Red Salud Mental CIBERSAM, Bioaraba, Spain

 Univ Autonoma Barcelona, Barcelona, Spain

 Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain

Rodriguez-Jimenez, R:
 Inst Invest Sanitaria Hosp 12 Octubre Imas12, Madrid, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain

Corripio, I:
 Hosp Santa Creu & Sant Pau, Inst Invest Biomed St Pau IIB St PAU, Psychiat Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Barcelona, Spain

 Univ Complutense Madrid UCM, CogPsy Grp, Madrid, Spain

Pomarol-Clotet, E:
 FIDMAG Germanes Hosp Res Fdn, Barcelona, Spain

 Univ Autonoma Barcelona UAB, Barcelona, Spain

Ibanez, A:
 Univ Alcala, Hosp Univ Ramon & Cajal, Dept Psychiat, IRYCIS, Alcala De Henares, Spain

 Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain

Usall, J:
 Inst Recerca St Joan de Deu, Parc Sanitari St Joan de Deu, Teaching Res & Innovat Unit, St Boi De Llobregat, Spain

Contreras, F:
 Bellvitge Univ Hosp, Psychiat Unit, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

Mas, S:
 Univ Barcelona, Dept Basic Clin Practice, Pharmacol Unit, Barcelona, Spain

 IDIBELL, Lhospitalet De Llobregat, Spain

Vazquez-Bourgon, J:
 Univ Hosp Marques de Valdecilla, Dept Psychiat, Santander, Spain

 August Pi & Sunyer Biomed Res Inst IDIBAPS, Clin & Expt Neurosci Area, Barcelona, Spain

 Inst Invest Sanitaria Valdecilla IDIVAL, Madrid, Spain

 Univ Cantabria, Santander, Spain

Cuesta, MJ:
 Biomed Network Res Ctr Mental Hlth CIBERSAM, Barcelona, Spain

Parellada, M:
 Univ Complutense, Hosp Gen Univ Gregorio Maranon, Inst Psychiat & Mental Hlth,Inst Invest Sanitaria, Dept Child & Adolescent Psychiat,Sch Med,CIBERSAM, Madrid, Spain

Gonzalez-Pinto, A:
 Univ Complutense, Hosp Gen Univ Gregorio Maranon, Inst Psychiat & Mental Hlth,Inst Invest Sanitaria, Dept Child & Adolescent Psychiat,Sch Med,CIBERSAM, Madrid, Spain

 Navarra Hlth Res Inst IdiSNA, Navarra, Spain

Hidalgo-Figueroa, M:
 Univ Cadiz, Dept Psychol, Neuropsychopharmacol & Psychobiol Res Grp, Cadiz, Spain

 Ctr Invest Biomed Red Salud Mental CIBERSAM, Santander, Spain

 Hosp Univ Puerta del Mar, Inst Invest & Innovac Biomed Cadiz, INiBICA, Cadiz, Spain

 Ctr Invest Biomed Red Salud Mental CIBERSAM Cadiz, Cadiz, Spain

Bernardo, M:
 Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit, Barcelona, Spain

 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

 Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain
ISSN: 09209964
Editorial
ELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 243 Número:
Páginas: 32-42
WOS Id: 000786666700005
ID de PubMed: 35231832
imagen Bronze, All Open Access; Bronze

MÉTRICAS